Although glucuronidation is considered an important pathway in aromatic amine-induced bladder cancer, benzidine glucuronidation has not been assessed in humans. Glucuronidation of benzidine was assessed with human liver microsomes and slices. Emulgen 911-treated microsomes exhibited a K m for benzidine of 0.8 ±0.06 mM and a V,,ô f 4.2 ±0.7 nmol/mg protein/min. A variety of agents were tested for their ability to inhibit benzidine /V-glucuronide formation. At 0.25 mM, estriol, 17-epiestriol, bilirubin, hyodeoxycholic acid and cyproheptadine were good inhibitors (<50% of control). Dose-dependent inhibition studies with estriol, testosterone and 4-aminobiphenyl demonstrated that each agent reached a plateau as its concentration was increased. When these agents were combined at maximal inhibitory concentrations, additive inhibition was observed. These results suggest that more than one UDPglucuronosyltransferase metabolizes benzidine. The cDNA clones pUDPGT h -l and -2 encode transferases which metabolize hyodeoxycholic acid and estrogen derivatives, but neither transferase catalyzed benzidine glucuronidation. Slices were used to assess metabolism by intact tissue and converted [ 3 H]benzidine (0.09 mM) to iV-acetylbenzidine. N-Glucuronides of both benzidine and Nacetylbenzidine were observed and represented 14-37% of the total recovered radioactivity. The amount of N-acetylbenzidine W-glucuronide observed was proportional to the amount of /V-acetylbenzidine produced. Thus, iV-glucuronidation appears to represent a major pathway for metabolism of benzidine in humans. The extent of ;V-acetylatJon affects the proportion of benzidine and Nacetylbenzidine glucuronidated by human liver slices.
Introduction
Occupational exposure of humans to aromatic amines has been associated with development of bladder cancer (1,2). Because factories often produce more than one aromatic amine, it has been difficult to attribute the development of bladder cancer to exposure to one specific amine. However, a recent study of Chinese workers exposed only to benzidine, an aromatic diamine, reported an overall 25-fold increased risk of bladder cancer (3) . The increased risk of bladder cancer correlated with the level of benzidine exposure, such that in highexposure jobs the risk was > 100-fold. Thus, exposure to benzidine is associated with the development of bladder cancer in occupationally exposed humans. Understanding the metabolism of benzidine in humans will contribute to our development of a mechanism-based model for benzidineinduced bladder cancer.
A/-Glucuronidation has been considered an important pathway in aromatic amine-induced bladder cancer (4) . UDPGlucuronosyltransferases are members of a class of enzymes located in the endoplasmic reticulum, encoded by a multigene family and responsible for glucuronidation of hundreds of xenobiotics and endogenous compounds (5) (6) (7) . Glucuronidaation is usually considered a detoxification step in which the more polar, water-soluble product is excreted. Certain transferases are subject to selective induction by agents, such as phenobarbital, which also induce cytochrome P-450. Glucuronosyltransferases have been identified which preferentially metabolize aromatic amines, i.e. a purified human transferase metabolizes 4-aminobiphenyl (8) (9) (10) . Important species differences exist for aromatic amine glucuronidation. The transferase which glucuronidates 4-aminobiphenyl in humans does not metabolize androsterone (10). In contrast, the rat contains a transferase which metabolizes both 4-aminobiphenyl and androsterone (a 3a-hydroxy steroid) (9) . UDP-Glucuronosyltransferase activity for benzidine has not been measured in humans. Benzidine Nglucuronide formation has been demonstrated with dog liver slices and detergent-treated microsomes (11, 12) . In contrast to dog, benzidine UDP-glucuronosyltransferase activity in rat liver was at the limit of detection (11). Because species differences exist, it is important to evaluate benzidine Nglucuronide formation in human tissues. ]UDP-glucuronic acid (279 mCi/ mmol, purity 99%) from ICN (Irvine, CA). /V-Acetylbenzidine was synthesized by acetylation of benzidine in glacial acetic acid as previously described (13) . All other reagents were purchased from Sigma Chemical Co. (St. Louis, MO). This study was approved by the St. Louis University Medical School Institutional Review Board and informed consent received before obtaining tissues. Normal human liver tissue was obtained from A (67-year-old white male, with metastatic colon cancer to the liver), B (46-year-old black female, with hepatocellular carcinoma), C (50-year-old white male, with aortic aneurysm; the liver was not transplanted because it was >30% fat), D (74-year-old white female, with metastatic colon cancer to the liver) and E (69-year-old white male, with metastatic colon cancer to the liver). Tissue samples A-C were brought to the laboratory immediately following surgery or autopsy and used for slice experiments. Samples D and E were provided frozen from the Cooperative Human Tissue Network. Microsomes were prepared from frozen tissues.
Materials and methods
To synthesize jV-glucuronides, an ethanol/aqueous reaction mixture, containing arylamine and D-glucuronic acid, was incubated either at room temperature (jV-acetylbenzidine) or 4°C (benzidine) for 24 h. Samples were purified on a Sep-Pak column. Mass spectral analysis was used to identify the products of these reactions. Using positive ion thermospray mass spectometry, the product of the reaction containing benzidine had a [M-H] + ion at mlz 361 which corresponds to benzidine W-glucuronide (11). Using negative ion electrospray ionization, the [M-H] + ion at mlz 401 identified /v'-acetylbenzidine W-glucuronide as the product of the /V-acetylbenzidine reaction (14) .
Hepatic microsomal W-glucuronidation of benzidine was assessed as previously described (11,12). Microsomes were incubated in 100 mM potassium phosphate buffer (pH 7.4), containing 20 mM MgCl 2 , 3.6 mM UDP-glucuronic acid and 0.05 mM [ 3 H]benzidine (final volume 0.25 ml) for 30 min at 37°C. Inhibitors were dissolved in DMSO; estrogens contained 1 mM ascorbic acid; solutions were stored at -70°C and used within 24 h of preparation; the final concentration of DMSO in the reaction mixture was 2%. At the end of the incubation, the pH was raised to 8.5 by adding 1 N NaOH and the reaction stopped with 0.5 ml methanol. The mixture was kept at 4°C for 30 min and centrifuged to remove precipitated protein. Supernatants were analyzed by HPLC. The HPLC system consisted of a 5 urn, 4.6 X 250 mm ODS ultrasphere® column attached to a guard column. The mobile phase for HPLC analysis started with 0.02 M potassium phosphate buffer (pH 6.8) and 15% methanol (v/v) (0-10 min), 15-50% linear gradient (10-27.5 min), 50-100% linear gradient (27.5-37.5 min) and 100% methanol (37JS-45 min) at a flow rate of 1 ml/min. Radioactivity in HPLC eluents was measured using a FLO-ONE radioanalytical detector. Similar results were obtained with solvent extraction (12) . Samples were extracted with 5 ml chloroform saturated with buffer (pH 8.5) and the radioactivity in the aqueous phase assessed. To achieve maximum transferase activity, microsomes were pretreated with different detergents for 60 min at 4°C with continuous stirring. Results are expressed as pmol/mg protein/min. To determine the apparent K m and V^ for benzidine, the concentration of UDP-glucuronic acid was kept constant (3.6 mM) and the concentration of benzidine varied from 0.1 to 2 mM. Data were subjected to non-linear regression analysis using the software program ENZFTTTER (Biosoft, Ferguson, MO). Apparent K m and V^ values are reported as the mean ± SEM from five separate samples.
The isolation, characterization and expression of the human UDP-glucuronosyltransferase cDNA clones pUDPGT h -1 and -2 have been previously described (15, 16) . Purified plasmid was combined with the carrier, Lipofectin®, and added to COS-1 cells for 5 h according to the manufacturer's instructions. After 48-96 h, cells were harvested and stored at -70°C until assay. Cells were resuspended in buffer containing 100 mM phosphate, pH 7.8, 1 mM phenylmethylsulfonyl fluoride, 1 Jig leupeptin/ml and then treated with 0.5
per mg protein for 60 min at 4°C. Activity was determined at 37°C in reaction mixtures (0.1 ml total volume) containing the indicated concentration of aglycone, 0.004 mM [ l4 C]UDP-glucuronic acid, 1 mM ascorbic acid, 10 mM MgCl2, 10 mM D-saccharic acid in 100 mM phosphate buffer, pH 7.8. Samples were subjected to HPLC analysis and expressed as a percentage of total radioactivity recovered.
To assess intact liver metabolism of benzidine, slices (0.1-0.2 g) were placed in 20 ml plastic scintillation vials containing 1 ml a-modified Eagles medium with 0.09 mM [ 3 H]benzidine at 37°C and gassed with 5% CO2/95% O2. Every hour, the samples were regassed. After the incubation, 1 N NaOH was added to raise the pH above 8.5, along with 2 ml ice-cold methanol. The samples were homogenized, centrifuged and supernatants frozen at -70°C. The amount of product formed was assessed by HPLC. Data were expressed as a percentage of the total amount of radioactivity recovered by HPLC.
Results
Benzidine A'-glucuronide synthesis was assessed with human liver microsomes. Emulgen 911, Triton X-100, CHAPS and Lubrol PX were the detergents tested to achieve optimal activation of microsomal benzidine UDP-glucuronosyltransferase activity. Emulgen 911, Triton X-100 and Lubrol PX elicited maximum activation, with 6-to 7-fold increases over untreated microsomes. Emulgen 911 was selected for use in subsequent studies. A range of detergent-to-protein ratios was examined for each sample to determine optimum activation. Usually, the optimum value was 0.3 or 0.5 mg detergent per mg protein. A Lineweaver-Burk plot of an Emulgentreated or -solubilized sample is illustrated in Figure 1 . Because K m values were similar for the treated and solubilized samples, all subsequent studies assessed only treated microsomes. In five separate liver samples, K m and V,,^ values were determined to be 0.8±0.06 mM and 4.2±0.7 nmol/mg protein/min respectively. To determine additional information about the transferase or transferases metabolizing benzidine, a variety of UDPglucuronosyltransferase substrates were analyzed to determine their effect on benzidine A'-glucuronide formation (Table I) . In these experiments, the concentration of [ 3 H]benzidine was kept at 0.05 mM while test agents were all evaluated at 0.25 mM. In general, the test agents exhibited similar effects in the five different liver samples examined. For the purpose of comparison, the following criteria were used to evaluate the effectiveness of test agents: agents with percentage of control values of <50% were considered good inhibitors, values of 51-80%, moderate inhibitors and values of 81-100%, poor inhibitors. The primary aromatic amines appeared to be moderate inhibitors, with 2-naphthylamine and 4-aminobiphenyl consistently the best inhibitors of this group. Within this group, p-aminobenzoic acid did not inhibit benzidine glucuronidation. Other agents which are poor inhibitors include yV-acetylbenzidine, A'-acetyl-p-aminophenol and phenol. p-Nitrophenol is a ubiquitous UDP-glucuronosyltransferase substrate and a moderate inhibitor of benzidine A'-glucuronide formation. Bilirubin was a good inhibitor. While estriol and 17-epiestriol were good inhibitors, hydroxy substitution at C-6 (6a-OH-estriol) resulted in a substantial loss of inhibitory activity. The catechol estrones (4-OH-estrone and 2-OHestrone), like testosterone and androsterone, appeared to be moderate inhibitors. The bile acid hyodeoxycholic acid was a good inhibitor, while hyocholic acid was only a moderate inhibitor. The tertiary amine drug cyproheptadine was a better inhibitor than imipramine. Results suggest some specificity in the inhibition of benzidine A'-glucuronide formation observed with test agents.
To further evaluate the results observed in Table I , inhibition by some agents were tested in a dose-response assay ( Figure  2 ). Estriol, testosterone and 4-aminobiphenyl exhibited doseresponsive inhibition, but each failed to completely inhibit benzidine A'-glucuronide formation. Inhibition by each agent reached a plateau as its concentration was increased. Estriol and testosterone exhibited maximum inhibition similar to that reported in Table I . In contrast, more inhibition was observed with 4-aminobiphenyl at 0.8 mM than 0.25 mM (Table I) . Because test agents exhibit an inhibition plateau rather than complete inhibition, the results suggest that more than one UDP-glucuronosyltransferase may metabolize benzidine. That is, the test agents used are UDP-glucuronosyltransferase substrates and their inhibition is thought to reflect metabolism by the transferase which metabolizes the test agent.
To assess complementary inhibition by the test agents used in Figure 2 , maximum effective inhibitory concentrations of two agents were combined (Table II) concentrations should elicit greater inhibition than either agent alone. The combination of either testosterone or 4-aminobiphenyl with estriol resulted in greater inhibition than observed with either agent alone. These results are consistent with more than one transferase metabolizing benzidine. To determine the specific human UDP-glucuronosyltransferase^) which metabolizes benzidine, two human transferases synthesized in COS-1 cells were assessed for their capacity to glucuronidate benzidine. Glucuronidation was monitored by HPLC. Using 0.25 mM 4-OH-estrone and estriol as substrates, pUDPGT h -2 metabolized 24 and 8% respectively of the total 0.004 mM [ l4 C]UDP-glucuronic acid present during a 60 min incubation. With pUDPGT h -l, 0.25 mM 4-OH-estrone elicited 0.6% metabolism. Using these same conditions with 1 mM benzidine as substrate, formation of benzidine A'-glucuronide was not detected with pUDPGT h -l or -2. To determine whether the lack of benzidine A'-glucuronide formation was due to the non-saturating concentration of UDP-glucuronic acid used, conditions utilized to demonstrate glucuronide formation in Table I (saturating concentration of UDP-glucuronic acid, with 0.15 mM [ 3 H]benzidine) were also evaluated. The latter condition did not demonstrate benzidine A'-glucuronide formation. Thus, these transferases do not appear to convert benzidine to benzidine A'-glucuronide under the assay conditions.
Human liver microsomes were used to qualitatively assess the amount of transferase activity metabolizing benzidine relative to that metabolizing 4-OH-estrone. Using the reaction conditions in Table I , this microsomal preparation elicited a 20% conversion of benzidine to benzidine A'-glucuronide. When this microsomal preparation was assayed using COS-1 cell incubation conditions, the metabolism of 0.004 mM ]benzidine A'-glucuronide had the same HPLC elution time. Thus, using the COS-1 cell assay conditions, similar human liver microsomal metabolism was observed for both substrates. This suggests that, if benzidine was being metabolized by the same transferases as 4-OHestrone, metabolism should have been observed when the corresponding transferase (i.e. pUDPGT h -l or -2) was used in the assay. These results further support the lack of metabolism of benzidine by pUDPGT h -l or -2.
To assess intact tissue metabolism human liver slices were incubated with 0.090 mM [ 3 H]benzidine for 2 h. Illustrated in Figure 3 is the HPLC profile of media from one such incubation. An early eluting peak (8.9 min) corresponded to the elution time of an authentic benzidine AZ-glucuronide standard. In addition, this early eluting peak was acid labile (pH 5.5) with a t\n of ~5 min (11, 14) . This peak was completely converted to benzidine by acid treatment. Thus, this product was identified as benzidine AZ-glucuronide and represented 24% of the total radioactivity recovered by HPLC.
During slice incubations, [ 3 H]benzidine is partially converted to A'-acetylbenzidine. In Figure 3 , AZ-acetylbenzidine represents 15% of the total radioactivity recovered by HPLC. AZ-Acetylbenzidine is converted to JV-acetylbenzidine A/'-glucuronide. The peak eluting at 20.7 min corresponds to the authentic Nacetylbenzidine A/'-glucuronide standard. This peak represents 13% of the total radioactivity. Like the A/-glucuronide of benzidine, A/-acetylbenzidine A/'-glucuronide is also acid labile (14) . Media from slice incubations were extracted with ethyl acetate to remove both benzidine and AZ-acetylbenzidine. Treatment of extracted media with acid resulted in quantitative hydrolysis of benzidine and AZ-acetylbenzidine AZ-glucuronides to their respective parent amine. Thus, both benzidine and Nacetylbenzidine AZ-glucuronides are made by human liver slices.
The formation of these AZ-glucuronides by human liver slices was assessed in different subjects. All liver slices were incubated with 0.090 mM [ Table III lists the percentages of each AZ-glucuronide, as well as the percentages of benzidine and A'-acetylbenzidine present. Benzidine AZ-glucuronide production ranged from 10 to 24%, while AZ-acetylbenzidine A/'-glucuronide production ranged from 4 to 18%. In general, slices produced more benzidine A/-glucuronide than AZ-acetylbenzidine A/'-glucuronide. Slices from five different subjects were incubated with 0.09 mM amount of A/-acetylbenzidine A/'-glucuronide produced was proportional to the extent of benzidine AZ-acetylation. For the most part, the greater the ratio of A/-acetylbenzidine to benzidine (last column on the right of Table III), the more A'-acetylbenzidine A/'-glucuronide synthesized. Peaks corresponding to each N-glucuronide were quantitatively converted to their parent amine by acid treatment. This provided conformational identification of each glucuronide. Thus, slices provide a dynamic method for assessing benzidine metabolism by human liver. A significant amount of AZ-acetylbenzidine A/'-glucuronide was formed in the presence of benzidine because more than one transferase may have metabolized benzidine and Nacetylbenzidine and non-saturating concentrations of substrates were present during slice incubations.
Discussion
This is the first study to identify benzidine AZ-glucuronide synthesis by human tissue. Both liver microsomes and slices produced this A/-glucuronide. The specific UDP-glucuronosyltransferase metabolizing benzidine was not identified. Inhibition studies were performed with UDP-glucuronosyltransferase substrates in an attempt to provide an insight into the transferase(s) which metabolizes benzidine. No inhibitor completely prevented benzidine glucuronidation. Dose-response studies demonstrated that as the concentration of an inhibitor increased, a plateau was reached. Furthermore, inhibition by estriol, testosterone and 4-aminobiphenyl complemented each other. This suggests that several transferases may be responsible for benzidine glucuronidation. In the dog, complete inhibition was achieved with estriol, 2-aminofluorene and 4-aminobiphenyl (12). 4-Aminobiphenyl was a competitive inhibitor, while estriol and 2-aminofluorene were non-competitive inhibitors. Because more than one transferase appears to be metabolizing benzidine in the human, kinetic studies to determine the type of inhibition exhibited by test agents are not reliable and, therefore, were not performed.
Some similarities and differences were observed compared to the inhibition study performed in the dog (12) . Both estriol and 17-epiestriol were good inhibitors for both species, with 6a-OH-estriol being less effective. Poor inhibitors include A/-acetylbenzidine, AZ-acetyU/T-aminophenol and phenol for both species. While hyodeoxycholic acid, testosterone and cyproheptadine were poor inhibitors in the dog, each was either a good or moderate inhibitor in humans. These results suggest differences between the dog and human transferases which glucuronidate benzidine.
Substrate preferences of individual UDP-glucuronosyltransferases have been determined in studies with cDNA expression systems. Preferential glucuronidation of hyodeoxycholic acid and certain estrogen derivatives has been demonstrated for the two human liver UDP-glucuronosyltransferase clones pUDPGT h -l and -2 (15, 16) . Because these compounds were effective inhibitors of benzidine glucuronidation (Table I) , N-glucuronidation of benzidine by pUDPGT h -l and -2 was assessed. pUDPGT h -2 is much more efficient than pUDPGT h -1 and is thought to be the primary enzyme for detoxification of these compounds. Assay of these expressed enzymes was designed to determine the presence or absence of benzidine transferase activity utilizing non-saturating concentrations of [ 14 C]UDP-glucuronic acid. Assay of pUDPGT h -l activity is limited due to the low efficiency of this enzyme. In contrast, considerable pUDPGT h -2 activity was observed. Because benzidine iV-glucuronide is labile with a t m of 104 min at pH 7.4 and 37°C (14) , long incubation times to increase the sensitivity of the COS-1 cell assay were not utilized. Neither pUDPGT h -l nor -2 appeared to glucuronidate benzidine under the assay conditions used. Assay conditions using a saturating concentration of UDP-glucuronic acid were also ineffective in demonstrating glucuronidation of benzidine by pUDPGT h -l or -2.
To evaluate the potential for benzidine N-glucuronide formation in vivo, liver slices were incubated with [ (Table HI) , substantial A/-glucuronide (10-24% of the total recovered radioactivity) was observed in each sample. A substantial amount of benzidine was N-acetylated to N-acetylbenzidine during the incubation. As a result, N-acetylbenzidine W-glucuronide formation was also observed. Glucuronidation appears to account for a significant amount of human hepatic metabolism of benzidine, with 14-37% of the total radioactivity recovered represented by the two N-glucuronides. A recent study has demonstrated that /V-acetylation can compete with N-glucuronidation. That is, N-glucuronidation of amides, such as A^JV'-diacetylbenzidine, does not occur (14) . Because rat liver slices rapidly converted N-acetylbenzidine to A/^V'-diacetylbenzidine, N-acetylbenzidine was not available for N-glucuronidation (14) . With human liver slices, once benzidine gets acetylated to N-acetylbenzidine, the latter gets iV-glucuronidated (Figure 3) . Surprisingly, little /vyV'-diacetylbenzidine was detected in human liver slices. Because little /vyV'-diacetylbenzidine was formed in humans, N-acetylation did not prevent glucuronidation, but rather altered the ratio of glucuronidation between benzidine and N-acetylbenzidine. The amount of N-acetylbenzidine W-glucuronide produced was proportional to the extent of benzidine N-acetylation (Table III) .
These results are consistent with a new model developed to explain possible differences in the metabolism of arylmonoamines and aryldiamines (14) . According to this hypothesis, N-acetylation of arylmonoamines to amides prevents their glucuronidation and alters excretion. In contrast, aryldiamines, such as benzidine, are capable of undergoing /V-acetylation and then W-glucuronidation. Glucuronides are proposed to be excreted and hydrolyzed to their parent amine by acidic urine. The latter can then be activated in bladder urothelium to initiate carcinogenesis.
